ClassID:

116052

C12Y207/10002 - CPC Classification

Classification description:

Transferases transferring phosphorus-containing groups (2.7); Protein-tyrosine kinases (2.7.10) Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Recent Application in this class:
#1
20260152751
2026-06-04

INTERFERING RNA FOR INHIBITING JAK1 GENE EXPRESSION AND USE THEREOF

#2
20260117232
2026-04-30

ANTISENSE OLIGONUCLEOTIDE, COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF FOR EXON SKIPPING

#3
20260092919
2026-04-02

REAGENT FOR MEASURING TYROSINE KINASE ACTIVITY, AND USE THEREOF

#4
20250367288
2025-12-04

DELIVERY OF MULTI-CYTOKINE SIGNALS BY OVEREXPRESSION OF WILD-TYPE OR MUTANT SIGNAL TRANSDUCTION MOLECULES

#5
20250361568
2025-11-27

COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID

#6
20250332277
2025-10-30

PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

#7
20250321223
2025-10-16

ENGINEERING CHEMICALLY INDUCIBLE SPLIT PROTEIN ACTUATORS (CISPA)

#8
20250289906
2025-09-18

MODULATION OF EXTRACELLULAR KINASE ACTIVITY AND FUNCTION FOR TREATMENT OF PAIN AND NEURODEGENERATIVE/NEUROIMMUNE DISEASE

#9
20250276089
2025-09-04

CO-DELIVERY OF INHIBITORY NUCLEIC ACIDS AND GENOME EDITORS FOR TUMOR THERAPY

#10
20250171784
2025-05-29

APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATION

#11
20250034576
2025-01-30

Double Stranded Oligonucleotide For Modulating JAK1 Expression

#12
20240376478
2024-11-14

Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment

#13
20240368566
2024-11-07

PYK2-DERIVED PEPTIDES FOR INHIBITING INVADOPODIA-MEDIATED CANCER METASTASIS

#14
20240350631
2024-10-24

ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS (CARS), CELLS EXPRESSING THE CARS AND RELATED METHODS

#15
20240189455
2024-06-13

COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION

#16
20240173353
2024-05-30

UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL AND APPLICATION THEREOF

#17
20240139320
2024-05-02

CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES FOR CONTROLLED AND SPECIFIC CAR T CELL ACTIVITY

#18
20240052015
2024-02-15

INDUCIBLE SIGNALLING PROTEIN

#19
20240041868
2024-02-08

Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

#20
20240025970
2024-01-25

LUNG TREATMENT COMPOSITIONS

#21
20240024511
2024-01-25

LENTIVIRAL VECTORS FOR THERAPEUTIC EXPRESSION OF BTK IN HEMATOPOIETIC CELLS

#22
20230313197
2023-10-05

IN VIVO LYMPHOVENOUS ANASTOMOSIS

#23
20230293643
2023-09-21

BRK PEPTIDES AND METHODS OF USE

#24
20230233606
2023-07-27

Cell

#25
20230085318
2023-03-16

POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF

#26
20220389075
2022-12-08

ENGINEERED T CELL RECEPTORS AND USES THEREOF

#27
20220380832
2022-12-01

METHODS FOR PREDICTING KINASE INHIBITOR RESISTANCE

#28
20220289842
2022-09-15

CHIMERIC INHIBITORY RECEPTOR

#29
20220213219
2022-07-07

Bruton's Tyrosine Kinase as Anti-Cancer Drug Target

#30
20220111015
2022-04-14

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

#31
20220002379
2022-01-06

SURROGATE CO-RECEPTORS FOR T CELLS AND METHODS OF USE

#32
20210403885
2021-12-30

CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY

#33
20210309714
2021-10-07

REDIRECTED CELLS WITH MHC CHIMERIC RECEPTORS AND METHODS OF USE IN IMMUNOTHERAPY

#34
20210238632
2021-08-05

VECTOR PRODUCTION IN SERUM FREE MEDIA

#35
20210230565
2021-07-29

BRUTON'S TYROSINE KINASE HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE

#36
20210198751
2021-07-01

COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID

#37
20210040469
2021-02-11

ENGINEERED CELL DEATH-INDUCING ENZYMES AND METHODS OF USE

#38
20210030753
2021-02-04

Methods, compositions, and uses of novel FYN kinase inhibitors

#39
20200345859
2020-11-05

FGFR3 binding molecules

#40
20200325458
2020-10-15

OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY

#41
20200316102
2020-10-08

Methods and pharmaceutical composition for the treatment of neurodegenerative disease

#42
20200277373
2020-09-03

ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF

#43
20200164046
2020-05-28

Inhibiting FAK-AKT interaction to inhibit metastasis

#44
20200115685
2020-04-16

BIFIDOBACTERIUM LONGUM

#45
20200113979
2020-04-16

Protein Kinase C-delta targeted therapy for treating radiation injury

#46
20190330310
2019-10-31

Membrane span-kinase fusion protein and the uses thereof

#47
20190276559
2019-09-12

Anti-TIE2 antibodies and uses thereof

#48
20190192533
2019-06-27

INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING

#49
20190169581
2019-06-06

Human serum albumin binding compounds and fusion proteins thereof

#50
20190161787
2019-05-30

Methods for predicting kinase inhibitor resistance

#51
20190153408
2019-05-23

#52
20190119271
2019-04-25

Conjugates comprising RIPK2 inhibitors

#53
20190100807
2019-04-04

Compositions and methods for detecting mutations in JAK2 nucleic acid

#54
20180360819
2018-12-20

ANTI-INFLUENZA VIRUS AGENT AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT

#55
20180311319
2018-11-01

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

#56
20180280527
2018-10-04

FGFR3 binding molecules

#57
20180237797
2018-08-23

METHODS FOR IN VITRO PRODUCTION OF PLATELETS AND COMPOSITIONS AND USES THEREOF

#58
20180179260
2018-06-28

Redirected cells with MHC chimeric receptors and methods of use in immunotherapy

#59
20180177845
2018-06-28

Method for treatment or prevention of a cancer

#60
20180125948
2018-05-10

Treatment of ocular neovascularization using anti-VEGF proteins

#61
20180104186
2018-04-19

METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA

#62
20180066327
2018-03-08

Methods to Accelerate Wound Healing in Diabetic Subjects

#63
20170335011
2017-11-23

Bruton's tyrosine kinase as anti-cancer drug target

#64
20170290821
2017-10-12

ANTI-INFLUENZA VIRUS AGENT AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT

#65
20170281768
2017-10-05

NOVEL NUCLEIC ACID MOLECULES WITH ANTITUMORAL ACTIVITY

#66
20170276688
2017-09-28

ANTI-HIMF ANTIBODIES TO TREAT LUNG DISEASES

#67
20170252322
2017-09-07

PKC delta inhibitors for use as therapeutics

#68
20170189404
2017-07-06

Bruton's tyrosine kinase as anti-cancer drug target

#69
20170174789
2017-06-22

Anti-TIE2 antibodies and uses thereof

#70
20170101401
2017-04-13

Benzimidazole analogues and related methods

#71
20170058270
2017-03-02

#72
20160281172
2016-09-29

Compositions and methods for detecting mutations in JAK2 nucleic acid

#73
20160250183
2016-09-01

PKC delta inhibitors for use as therapeutics

#74
20160199402
2016-07-14

Methods for treating ischemia-reperfusion injury

#75
20160101171
2016-04-14

MELK epitope peptides and vaccines containing the same

#76
20160076011
2016-03-17

Human serum albumin binding compounds and fusion proteins thereof

#77
20160053024
2016-02-25

Bruton's tyrosine kinase as anti-cancer drug target

#78
20150297611
2015-10-22

Inhibition of histone methyltransferase for cardiac reprogramming

#79
20150218229
2015-08-06

Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease

#80
20150184249
2015-07-02

Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)

#81
20150133389
2015-05-14

Methods of treatment of cancer using SRC-modulating peptides

#82
20150094226
2015-04-02

Crystal Structure of a NEF/SdAb19 Complex and Uses Thereof

#83
20150047065
2015-02-12

Binding molecules with antitumoral activity

#84
20150011530
2015-01-08

Cyclic molecules as bruton's tyrosine kinase inhibitors

#85
20150011417
2015-01-08

Membrane span-kinase fusion protein and the uses thereof

#86
20150004101
2015-01-01

Treatment of ocular neovascularization using anti-VEGF proteins

#87
20140336171
2014-11-13

Azaindoles useful as inhibitors of Janus kinases

#88
20140073593
2014-03-13

Bruton's tyrosine kinase as anti-cancer drug target

#89
20130150294
2013-06-13

Na+/K+-ATPase-specific peptide inhibitors/activators of Src and Src family kinases

#90
20120245173
2012-09-27

Inhibition of activated cdc42-associated kinase 1

#91
20120165395
2012-06-28

Bruton's tyrosine kinase as anti-cancer drug target

#92
20120165307
2012-06-28

Azaindoles useful as inhibitors of janus kinases

#93
20120156180
2012-06-21

COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES

#94
20120003653
2012-01-05

Compositions and methods for detecting mutations in JAK2 nucleic acid

#95
20110251255
2011-10-13

Methods and compositions for inhibiting the proliferation of cancer cells

#96
20110212115
2011-09-01

MELK epitope peptides and vaccines containing the same

#97
20110206689
2011-08-25

Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof

#98
20110135654
2011-06-09

Prostate cancer related gene STYK1

#99
20100311743
2010-12-09

Azaindoles useful as inhibitors of Janus kinases

#100
20100287636
2010-11-11

COMPOSITIONS AND METHODS FOR INHIBITING INDUCIBLE T CELL KINASE (ITK) AND TREATING ASTHMA AND BRONCHIAL INFLAMMATIONS

#101
20100261776
2010-10-14

BRUTON'S TYROSINE KINASE AS ANTI-CANCER DRUG TARGET

#102
20100151452
2010-06-17

Methods and Systems for Searching for Regulators of the Fer Protein and for Monitoring the Effects of the Fer Protein

#103
20100056446
2010-03-04

Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases

#104
20100028355
2010-02-04

Anti-HIMF antibodies to treat lung diseases

#105
20100009451
2010-01-14

COMPOSITIONS AND METHODS FOR SPECIFICALLY SILENCING A TARGET NUCLEIC ACID

#106
20090082294
2009-03-26

Diagnosis, prevention and treatment of cancer

#107
20070203142
2007-08-30

Azaindoles useful as inhibitors of janus kinases

#108
20070020253
2007-01-25

Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof

#109
20070004624
2007-01-04

Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions

#110
20060287273
2006-12-21

Methods and reagents for inhibiting cell proliferation

#111
20060127903
2006-06-15

Marker for cancer

#112
20050063973
2005-03-24

Diagnosis, prevention and treatment of cancer

#113
20050026172
2005-02-03

siRNA libraries optimized for predetermined protein families